Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 06, 2011
Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
Calando's management remains optimistic about deals in 2011. But some industry observers expect that it will take years of continued advancement in the RNAi field and a shift in its players' expectations before major deals are consummated.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - Silence Says It Is In Talks Over Potential Sale
September 9, 2010 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News - In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations
November 4, 2010 / Gene Silencing News